Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

Germinal center B-cell-like versus non-germinal center B-cell-like as important prognostic factor for localized nodal DLBCL.

Habara T, Sato Y, Takata K, Iwaki N, Okumura H, Sonobe H, Tanaka T, Orita Y, Abd Al-Kader L, Asano N, Ennishi D, Yoshino T.

J Clin Exp Hematop. 2012;52(2):91-9.

2.

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.

Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.

J Clin Oncol. 2008 Oct 1;26(28):4587-94. doi: 10.1200/JCO.2007.15.9277. Epub 2008 Jul 28.

PMID:
18662967
3.

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.

Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, Rosenwald A, Jack A, Sundstrom C, Cogliatti S, Trougouboff P, Boudova L, Ysebaert L, Soulier J, Chevalier C, Bron D, Schmitz N, Gaulard P, Houlgatte R, Gisselbrecht C.

J Clin Oncol. 2011 Nov 1;29(31):4079-87. doi: 10.1200/JCO.2011.35.4423. Epub 2011 Sep 26.

PMID:
21947824
4.

High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.

Li ZM, Huang JJ, Xia Y, Zhu YJ, Zhao W, Wei WX, Jiang WQ, Lin TY, Huang HQ, Guan ZZ.

Eur J Haematol. 2012 Jun;88(6):510-7. doi: 10.1111/j.1600-0609.2012.01778.x. Epub 2012 Mar 27.

PMID:
22413767
5.

Comparison of two different immunohistochemical algorithms identifying prognostic subgroups of DLBCL.

Jabłońska J, Jesionek-Kupnicka D, Potemski P, Kowalik A, Sygut J, Kordek R.

Pol J Pathol. 2010;61(3):124-32.

6.

BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.

Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, Chan WC.

Clin Cancer Res. 2011 Dec 15;17(24):7785-95. doi: 10.1158/1078-0432.CCR-11-0267. Epub 2011 Sep 20.

7.

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.

Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, Braziel RM, Geng H, Iqbal J, Lenz G, Vose JM, Hans CP, Fu K, Smith LM, Li M, Liu Z, Gascoyne RD, Rosenwald A, Ott G, Rimsza LM, Campo E, Jaffe ES, Jaye DL, Staudt LM, Chan WC.

Clin Cancer Res. 2009 Sep 1;15(17):5494-502. doi: 10.1158/1078-0432.CCR-09-0113. Epub 2009 Aug 25.

8.

The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab.

Benesova K, Forsterova K, Votavova H, Campr V, Stritesky J, Velenska Z, Prochazka B, Pytlik R, Trneny M.

Neoplasma. 2013;60(1):68-73. doi: 10.4149/neo_2013_010.

PMID:
23067219
9.

Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation.

Costa LJ, Feldman AL, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Ansell SM.

Br J Haematol. 2008 Jul;142(3):404-12. doi: 10.1111/j.1365-2141.2008.07207.x. Epub 2008 May 15.

PMID:
18492096
10.

Clinicopathologic analysis of localized nasal/paranasal diffuse large B-cell lymphoma.

Toda H, Sato Y, Takata K, Orita Y, Asano N, Yoshino T.

PLoS One. 2013;8(2):e57677. doi: 10.1371/journal.pone.0057677. Epub 2013 Feb 28.

11.

Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.

Liu YH, Xu FP, Zhuang HG, Lai KC, Xie D, Luo DL, Li L, Luo XL, Xu J, Zhang MH, Zhang F, Li HM.

Hum Pathol. 2008 Jun;39(6):875-84. doi: 10.1016/j.humpath.2007.10.013. Epub 2008 Apr 28.

PMID:
18440593
12.

Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?

Laszlo D, Pruneri G, Andreola G, Radice D, Calabrese L, Rafaniello PR, Nassi L, Sammassimo S, Alietti A, Agazzi A, Vanazzi A, Martinelli G.

Int J Surg Pathol. 2011 Aug;19(4):417-24. doi: 10.1177/1066896909345596. Epub 2009 Sep 30.

PMID:
19793830
13.

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.

Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, Goy A, Witzig TE, Czuczman MS.

Cancer. 2011 Nov 15;117(22):5058-66. doi: 10.1002/cncr.26135. Epub 2011 Apr 14.

14.

MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.

Yoon SO, Jeon YK, Paik JH, Kim WY, Kim YA, Kim JE, Kim CW.

Histopathology. 2008 Aug;53(2):205-17. doi: 10.1111/j.1365-2559.2008.03076.x.

PMID:
18752503
15.

[Prevalence of germinal center B-cell-like and non-germinal center B-cell-like types of diffuse large B-cell lymphoma in Shanghai, China].

Chen Y, Chen H, Fu K, Zhu XZ, Irons R.

Zhonghua Bing Li Xue Za Zhi. 2010 May;39(5):313-8. Chinese.

PMID:
20654154
16.

[Comparative study of heterogeneity of extranodal and nodal diffuse large B cell lymphoma].

Yin HF, Li T.

Beijing Da Xue Xue Bao. 2007 Apr 18;39(2):158-62. Chinese.

17.

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.

Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppä S.

Eur J Haematol. 2009 May;82(5):364-72. doi: 10.1111/j.1600-0609.2009.01222.x. Epub 2009 Jan 9.

PMID:
19141121
18.

Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab.

Ilić I, Mitrović Z, Aurer I, Basić-Kinda S, Radman I, Ajduković R, Labar B, Dotlić S, Nola M.

Int J Hematol. 2009 Jul;90(1):74-80. doi: 10.1007/s12185-009-0353-y. Epub 2009 Jun 3.

PMID:
19495929
19.

[Significance of microRNA-146b-5p in diffuse large B-cell lymphoma and its relationship with risk assessment].

Cao QW, Li HY, Yao XX, Wang JF.

Zhonghua Xue Ye Xue Za Zhi. 2012 Dec;33(12):1010-4. Chinese.

PMID:
23363792
20.

[Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases].

Lin L, Min M, Bi CF, Wang XQ, Luo TY, Zhao S, Zhang WY, Liu WP.

Zhonghua Bing Li Xue Za Zhi. 2011 Apr;40(4):220-6. Chinese.

PMID:
21615994

Supplemental Content

Support Center